Matt Brow is president and general manager of Avalere Health, Inovalon's data-driven advisory business.

He leads all of the firm’s operations, practices, and functions. With extensive experience managing cross-functional teams, Matt has engaged internal and external healthcare stakeholders to find consensus and achieve stable business growth.

Most recently, Matt was senior vice president, Operations, for the U.S. Oncology Network at McKesson Specialty Health, responsible for developing, planning, and directing the operations of The Network across a multi-state territory. Previously, he held roles at McKesson and its predecessor company, U.S. Oncology, leading public policy, mergers and acquisitions, business development, go-to-market strategy, sales, reimbursement strategy, federal and state government relations, and communications. Prior to joining U.S. Oncology, he was a consultant, advising clients on state government affairs strategy across a wide-range of healthcare and political issues.

Matt has a BA in history and political science from the University of Richmond.

Authored Content

As policymakers explore opportunities to reform Medicare Part B, a tiered average sales price (ASP) add-on payment may be under consideration to align system incentives and curb spending.

Matt Kazan and Amy Schroeder bring unique understandings of how policy and clinical data drive healthcare markets.

Former U.S. Congressman Jason Altmire has joined Avalere Health as a senior advisor, offering his deep understanding of the policy-making process to inform business strategy.

Yesterday, the Department of Health and Human Services Office of Inspector General released a proposed rule redefining the current safe harbor for pharmaceutical manufacturer discounts and rebates to entities like health plans and pharmacy benefit managers (PBMs).

Avalere analysis finds that most of the payment reductions from the proposed International Pricing Index Model for Part B drugs would affect oncologists, rheumatologists, and ophthalmologists.

Avalere experts examine the current drug pricing policy landscape and what potential changes stakeholders should prepare for.

Clinicians who treat certain types of cancer may be better positioned to earn performance-based payments under the Oncology Care Model.

Outcomes-based contracts most common in cardiovascular disease, infectious disease, and oncology.

More than 25% of patients with breast and lung cancers have been treated by a participating Oncology Care Model doctor. Participation trends could accelerate the transformation of treatment for some cancers, according to Avalere experts.

Moving certain Part B drugs to Part D, a proposal being evaluated by the Trump administration, would have disparate financial impacts on patients.

Moving certain Part B drugs to Part D, a proposal being evaluated by the Trump administration, would have disparate financial impacts on patients.

President Trump is expected to announce a drug pricing plan in the coming weeks; signals from the White House indicate potential alignment around several priority policies.

Rural hospitals will see an average 2.7% net increase of Part B payments.

The shift from volume to value has played a significant role in shaping current payer behavior in the oncology space.

Kenny Kan has joined the Avalere team leading the firm's actuarial analytics. Prior to joining Avalere, Kan served as the Chief Actuary at Humana and CareFirst.